Abcam plc (ABCM)

Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period on 12 September 2022.

Companies Reporting Before The Bell • Wipro (NYSE:WIT) is projected to report quarterly earnings at $0.08 per share on ...

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.

Today we will run through one way of estimating the intrinsic value of Abcam plc ( LON:ABC ) by taking the expected...

Abcam (LON:ABC) has had a rough month with its share price down 11%. It is possible that the markets have ignored the...

Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Abcam PLC Sponsored ADR (ABCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting refe

While Abcam plc ( LON:ABC ) shareholders are probably generally happy, the stock hasn't had particularly good run...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications.

Today we will run through one way of estimating the intrinsic value of Abcam plc ( LON:ABC ) by projecting its future...

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged ...

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of ...

Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 68.7% to $1.84 during Tuesday's pre-market session. The ...

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and ...

Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.

In recent trading, shares of Abcam PLC (ABCM) have crossed above the average analyst 12-month target price of $22.33, changing hands for $23.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Abcam (LON:ABC) has had a great run on the share market with its stock up by a significant 15% over the last three...

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership.

Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR.

CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period. SUMMARY PERFORMANCE 12 mont

Companies Reporting Before The Bell • Optical Cable (NASDAQ:OCC) is expected to report earnings for its third ...

Abcam plc(NASDAQ: ABCM)has agreed to acquireBioVision Inc, a wholly-ownedBoai NKY Medical Holdings ...

Before 10 a.m. ET Tuesday, 64 stocks made new 52-week lows. Key Facts: TotalEnergies (NYSE:TTE) was the ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

They provide the infrastructure and sell the tools that biomedical researchers need to make breakthroughs.

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..